scholarly journals Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome

2019 ◽  
Vol 26 (6) ◽  
pp. 818-829.e9 ◽  
Author(s):  
Suman Rao ◽  
Deepak Gurbani ◽  
Guangyan Du ◽  
Robert A. Everley ◽  
Christopher M. Browne ◽  
...  
Keyword(s):  
F1000Research ◽  
2013 ◽  
Vol 2 ◽  
pp. 144 ◽  
Author(s):  
Ye Hu ◽  
Jürgen Bajorath

Compound promiscuity is defined as the ability of a small molecule to specifically interact with multiple biological targets. So-defined promiscuity is relevant for drug discovery because it provides the molecular basis of polypharmacology, which is increasingly implicated in the therapeutic efficacy of drugs. Recent studies have analyzed different aspects of compound promiscuity on the basis of currently available activity data. In this commentary, we present take-home messages from these studies augmented with new results to generate a detailed picture of compound promiscuity that might serve as a reference for further discussions and research activities.


F1000Research ◽  
2014 ◽  
Vol 3 ◽  
pp. 233 ◽  
Author(s):  
Jürgen Bajorath

Compounds with apparent activity in a variety of assays might disable target proteins or produce false assay signals in the absence of specific interactions. In some instances, such effects are easy to detect, in others they are not. Observed promiscuity of compounds might be due to such non-specific assay artifacts. By contrast, promiscuity might also result from specific interactions with multiple targets. In the latter case, promiscuous compounds can be attractive candidates for certain therapeutic applications. However, compounds with artificial activity readouts are often not recognized and are further progressed, which presents a substantial problem for drug discovery. In this context, the concept of PAINS (pan-assay interference compounds) should be seriously considered, which makes it possible to eliminate flawed compounds from the discovery pipeline, even if their activities appear to be sound at a first glance.


2013 ◽  
Vol 18 (13-14) ◽  
pp. 644-650 ◽  
Author(s):  
Ye Hu ◽  
Jürgen Bajorath

2011 ◽  
Vol 28 (1) ◽  
pp. 140-141 ◽  
Author(s):  
S. A. Canny ◽  
Y. Cruz ◽  
M. R. Southern ◽  
P. R. Griffin

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 1227 ◽  
Author(s):  
Ye Hu ◽  
Jürgen Bajorath

For the generation of contemporary databases of bioactive compounds, activity information is usually extracted from the scientific literature. However, when activity data are analyzed, source publications are typically no longer taken into consideration. Therefore, compound activity data selected from ChEMBL were traced back to thousands of original publications, activity records including compound, assay, and target information were systematically generated, and their distributions across the literature were determined. In addition, publications were categorized on the basis of activity records. Furthermore, compound promiscuity, defined as the ability of small molecules to specifically interact with multiple target proteins, was analyzed in light of publication statistics, thus adding another layer of information to promiscuity assessment. It was shown that the degree of compound promiscuity was not influenced by increasing numbers of source publications. Rather, most non-promiscuous as well as promiscuous compounds, regardless of their degree of promiscuity, originated from single publications, which emerged as a characteristic feature of the medicinal chemistry literature.


ACS Omega ◽  
2019 ◽  
Vol 4 (2) ◽  
pp. 2758-2765 ◽  
Author(s):  
Erik Gilberg ◽  
Jürgen Bajorath

Sign in / Sign up

Export Citation Format

Share Document